49 results
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
disasters, and the indirect and/or long-term impact of inflation, will affect our business operations, clinical trials, or financial condition; and
any … based on their potential to offer new therapeutic approaches and long-term patient benefits.
We aim to maximize value to our shareholders
10-K
2024 FY
EX-97.1
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
of the following:
Annual bonuses and other short- and long-term cash incentives
Stock options
Stock appreciation rights
Restricted stock units
Performance rights
10-K
2024 FY
EX-4.2
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
(Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). Computershare shall have
8-K
EX-10.2
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
to be shown as a long term liability on a balance sheet prepared in accordance with GAAP, (e) all capitalized lease obligations of such person, (f … indebtedness for borrowed money or money due under any long term leasing or factoring arrangement that (a) involves an obligation greater than $250,000
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Jul 24
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
9:00am
with a person’s breathing, decreasing oxygen uptake, resulting in poor-quality sleep1. Untreated sleep apnea leads to serious long-term adverse health outcomes
S-1/A
EX-10.10
jsbahynvkmo7k3
17 Jul 24
IPO registration (amended)
8:47am
S-1/A
nmbre3
17 Jul 24
IPO registration (amended)
8:47am
S-1
an2fek1v6 bdef
3 Jul 24
IPO registration
6:29am
8-K
EX-99.1
98od9 2s0k1f2k7c
30 May 24
Other Events
8:30am
8-K
EX-10.1
10r9m
5 Mar 24
Departure of Directors or Certain Officers
6:11am
8-K
s8cj74zs5q49dc5997zm
5 Mar 24
Departure of Directors or Certain Officers
6:11am
10-Q
dpush6 kdbx
14 Feb 24
Quarterly report
6:16am
10-Q
EX-10.14
ndebhsko81itahrgfz
14 Feb 24
Quarterly report
6:16am
8-K
EX-99.1
m3169xcq
17 Jan 24
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
6:05am
6-K
EX-99.1
ykf seadq
26 Oct 23
Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
6:02am
6-K
EX-99.1
iadgblmlj7qm
1 Sep 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
33rgxycn0brivnras7
22 Aug 23
Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
6:01am